BioSpace News Archive

Olema Pharmaceuticals, Inc. announced that the Company will present at the following upcoming investor conferences in November.

Zentalis® Pharmaceuticals, Inc. announced that on November 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 271,000 shares of the Company’s common stock to five newly hired employees.

Viemed Healthcare, Inc. announced that it has reported its financial results for the three and nine months ended September 30, 2023.

LimFlow SA announced that it has entered into a definitive agreement to be acquired by Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 9, 2023 to report its third quarter 2023 financial results and provide a corporate update.

NANOBIOTIX announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering reserved to specified categories of investors consisting of an offering of its American Depositary Shares.

Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the quarter ended on September 30, 2023.

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 by conference call on Wednesday, November 8, 2023 at 4:30 PM ET.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.